FDA Approves Pfizer’s BEQVEZ™ Gene Therapy for Hemophilia B
Pfizer announced on Friday that the U.S. FDA has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate
Read more
DISEASES
Evotec and Variant Bio Partner to Discover and Develop Fibrosis Treatments
The Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read more
NIH Researchers Improve Cancer Drug Response Prediction Using scRNA-seq Data AI Model
In a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read more
Ventus’ NLRP3 Inhibitor Shows Potential for CNS Diseases in Phase 1 Trial
Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more
Nutcracker’s mRNA Drug Candidate for Prostate Cancer Effectively Targets CD3 T cells
Preclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read more
Vertex Expands Immunotherapy Capabilities with $4.9bn Alpine Acquisition
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read more
Pfizer’s ABRYSVO® Shows Promising Results in Phase 3 Trial Targeting RSV Prevention in High-Risk Adults
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read more
FDA Approves J&J and Bristol Myers Cell Therapies for Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read more
US FDA Approves First Tumor-agnostic HER2-directed Therapy
The US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read more
AstraZeneca Expands Rare Disease Pipeline with Amolyt Pharma Acquisition
AstraZeneca has announced it is set to acquire Amolyt Pharma, a French clinical-stage biotechnology company focused on developing novel treatments
Read more